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ABSTRACT
LPA is a component of oxidized low density lipoproteins (oxLDL) which has
been shown to accumulate in human atherosclerotic plaques. Tissue factor {TF) is the
principal initiator of blood coagulation. Tissue factor upregulation in atherosclerotic
plaque can lead to undesirable vascular thrombosis. The generation of reactive oxygen
species (ROS), which act as signaling molecules in the vascular system, is enhanced in
response to injury and has been associated with a procoagulant state and the progression

..

, to the increased expression
of atherosclerotic disease. Oxidative stress might contribute
of proatherosclerotic genes at sites of vascular injury, including TF. Little is known about
the regulation of TF by LPA in smooth muscle cells (SMC) which is a major player in the
process of atherosclerosis. Data generated by this study demonstrate that LPA markedly
induces TF expression in rat aorta smooth muscle cells (RASMCs) and human aorta
smooth muscle cells (HASMCs). The signaling pathways involved are multiple. One
signaling pathway demonstrates that LPA activates Gai protein which in tum activates
PKC and MAPK cascades to induce Egr-1 that is involved in turning on TF gene in the
nucleus. The other pathways include LPA-induced release of ROS and calcium, mediated
by PLA2 or without PLA2 involvement. Our data suggest that elevated LPA have
potential atherogenic and thrombogenic actions by inducing TF expression and ROS
release. Understanding the mechanisms involved could provide new insights into
atherosclerosis, thrombosis and restenosis after angioplasty.
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I. BACKGROUND AND INTRODUCTION
Cardiovascular diseases are the number one cause of death in the United States
[Groer, 2001]. Atherosclerosis is a progressive cardiovascular disease characterized by
accumulation of lipids and fibrous elements in the arteries. Atherosclerosis primarily
affects elastic arteries (e.g., aorta) and large and medium-sized muscular arteries (e.g.,
coronary arteries). This disease is the primary cause of heart disease and stroke. In
Westernized societies, it is the underlying cause of about 50% of all deaths [Lusis, 2000].
THE NORMAL ARTERY:
The arterial wall normally consists of three well-defined concentric layers: the
innermost layer is called the intima, the middle layer is called the media, and the
outermost layer is known as the adventitia. These three layers are demarcated by
concentric layers of elastin known as the internal elastic lamina (which separates the
intima from the media), and the external elastic lamina (which separates the media from
the adventitia).
The luminal surface of arteries is lined by a single contiguous layer of endothelial
cells that sits upon a basement membrane of extracellular matrix, and is bordered by the
internal elastic lamina. The amount of extracellular matrix and elastin in the internal
elastic lamina is most prominent in medium and large sized arteries.
The media consists of a single cell type, smooth muscle cells. There can be one or
many layers of smooth muscle cells depending on the size of the artery [Keaney Jr,
2000].The vascular smooth muscle has been shown to be a pleiotropic cell capable of
phenotypic changes associated with the synthesis of many biologically active molecules
1

that mediate cell growth, death, and migration, as well as matrix modulation and
inflammation. These activities of vascular smooth muscle play important roles in
physiological vascular functions, such as vascular remodeling, and in pathological
disorders, such as atherosclerosis, restenosis, transplant vasculopathy, and other vascular
diseases [Alexander and Dzau, 2000]. The media can vary in size considerably based on
the function of a given artery. For example, in very small arteries the media may only be
one cell layer thick, or not present at all, whereas in large arteries like the aorta the media
may be many cell layers thick and consist of considerable elastin as part of the
extracellular matrix.
Beyond the external elastic lamina, the adventitia is the outermost layer of the artery.
The adventitia typically consists of a loose matrix of elastin, smooth muscle cells,
fibroblasts, and collagen. This layer contains small vessels that gives rise to vasa
vasorum. Most of the neural input into blood vessels also traverse the adventitia [Keaney
Jr, 2000; Avrum et al, 1999]
ATHEROSCLEROSIS:

·The early lesions of atherosclerosis (fatty streaks) consist of subendothelial
accumulations of cholesterol-engorged macrophage, called foam cells. These lesions are
not clinically significant, but they are the precursors of more advanced lesions
(atheromatous plaques). An atheromatous plaque consists of a raised focal plaque within
the intima, having a necrotic core of lipid and a covering fibrous cap. The superficial
fibrous cap is composed of smooth muscle cells with a few leukocytes and relatively
dense connective tissue. The lipid necrotic core lies deeper to the fibrous cap and it
2

consists of a disorganized mass of lipid material, cholesterol clefts, cellular debris, lipid
laden foam cells, fibrin, thrombus in various stages of organization, and other plasma
proteins. The lipids in the core are primarily cholesterol and cholesterol esters. Foam cells
predominantly derive from lipid-laden macrophages, but smooth muscle cells can also
take up lipids to become foam cells. A primary initiating event in atherosclerosis is the
accumulation of LDL in the subendothelial matrix. Accumulation is greater when levels
of circulating LDL are raised [Schoen and Cotran, 1999]. Native LDL is not taken up by
macrophages rapidly enough to generate foam cells, and it has been shown that trapped
LDL does undergo modification, including oxidation, lipolysis, proteolysis and
aggregation. These modifications contribute to inflammation and foam cell formation
[Boren et al, 1998]. If the hypercholesterolemia persists, smooth muscle cell proliferation
and extracellular matrix deposition in the intima continue and are the major processes that
convert a fatty streak into a mature fibrofatty atheroma (plaque), accounting for the
progressive growth of atherosclerotic lesions [Schoen and Cotran, 1999]. Plaques can
become increasingly complex, with calcification, ulceration at the luminal surface, and
hemorrhage from small vessels that grow into the lesion from the media of the blood
vessel wall. The most important clinical complication is acute occlusion due to super
imposed thrombosis which usually occurs on disrupted lesions (those with rupture,
ulceration, erosion, or hemorrhage) [Lusis, 2000; Schoen and Cotran 1999]. Acute
thrombosis can lead to arterial occlusion and consequently provoke myocardial infarction,
unstable angina, stroke and sudden death [Tremoli et al, 1999].
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TISSUE FACTOR:
Pathological studies have identified tissue factor (TF), present in cells and in the extra
! I
cellular debris within the atherosclerotic plaque, as a candidate molecule responsible
for

the thrombogenicity associated with the plaque rupture [Fuster et al, 1997]. TF, a small

,, cascade
,, and is
(47kd) transmembrane glycoprotein, is the principal initiator of the clotting
considered to be a major regulator of hemostasis and thrombosis [Marmur et al, 1994;

.

.,..
Edgington et al, 1991]. TF initiates the extrinsic pathway of blood coagulation
.• events of this cascade are thrombin generation and
[Schonbeck et al, 2000]. The ultimate

thrombin-catalyzed events which lead to thrombus formation and stabilization [Carson
l &
and Brozna, 1993]. TF might also affect intimal area by increasing matrix accumulation

and stimulating smooth muscle cell (SMC) migration and proliferation contributing to
athermatous plaque development [Hasenstab et al, 2000]. The data so far available from
samples retrieved by coronary atherectomy suggests that TF plays a critical rule in
determining atherosclerotic plaque thrombogenicity. Thrombus evident on histology has
been found only in TF-positive plaques [Marmur et al, 1994] and TF antigen and activity
were higher in the plaques with complex morphology or coronary thrombosis at
,· I activity were also higher in
,
I the
angiography [Ardissino et al, 1997]. TF concentration and

plaques taken from patients with unstable angina or myocardial infarction, and in patients
with de novo angina
... as compared to stable patients [Ardissino et al, 1997; Annex et al,
1995].

4

In normal arteries, little or no TF is found in the intima or media, whereas TF is
abundant in the adventitia [Merlini et al, 1999]. TF is not constitutively expressed by the
normal artery endothelium or by cellular components of blood. In healthy tissue, this
distribution allows the endothelium to provide an anticoagulant surface lining the vessel
lumen, and the adventitia a procoagulant surface around the vessel, ensuring prompt
initiation- of coagulation in the event of vascular rupture [Mc Vey, 1999]. Vascular
smooth muscle cells (SMCs) is a major source of arterial TF [Speidel et al, 1995]. In
animal models of arterial injury, TF is rapidly induced in the SMCs of the media and
accumulates in the SMCs of the developing neointima [Merlini et al, 1999; Gertz et al,
1998; Annex et al, 1995].
TF is also abundant m macrophages, and SMCs of atherosclerotic plaques
[Hatakeyama et al, 1997; Wilcox et al, 1989]. It has also been detected in the extracellular
matrix and in the acellular lipid rich core in atherosclerotic plaques [Moreno et al, 1996;
Wilcox et al,

1989]. Induction

of TF in human endothelial cells and

monocyte/macrophages has been extensively studied [Siess et al, 1999; Thiruvikraman et
al, 1996]. In contrast, little is known about the regulation of its expression in human
arterial SMC and in the cell and lipid-rich core of the atheromatous plaque.
LYSOPHOSPHATIDIC ACID (LPA):

Oxidized LDL is a key factor in the pathogenesis of atherosclerosis. Lysophosphatidic
acid is formed during mild oxidation of LDL and is the active compound in mildly
oxidized LDL and minimally modified LDL. It has been found that LPA also accumulates
in the lipid-rich core of atherosclerotic plaques [Fernandez-Ortiz et al, 1994].
5

Experimental evidence indicates that the lipid-rich atheromatous core and not the exposed
collagen is thrombogenic initiator in ruptured plaques [Goetzl et al, 1998]. Our group has
recently reported that LPA dramatically induces TF expression in RASMCs (TF rnRNA
was induced eight folds and TF protein and TF total activity were also increased). These
results indicate that LPA might be a thrombogenic risk factor that plays an important role
in pathogenesis of atherosclerosis. SMC is known to be one of the important players in
atherosclerotic lesion development. However, little is known about the regulatory
mechanisms governing the induction of TF expression by LPA in RASMCs.
ROLE OF REACTIVE OXYGEN SPECIES IN THE ARTERIAL WALL:
Reactive oxygen species (ROS) are a family of molecules including molecular oxygen
and its derivatives produced in all aerobic cells. Many ROS possess unpaired electrons
and thus are free radicals. These include molecules such as superoxide anion (Ot),
hydroxyl racial (HO'), nitric oxide (NO'), and lipid radicals. Other reactive oxygen
species, such as hydrogen peroxide (H202), peroxynitrite (ONOO-), and hypochlorous
acid (HOCl), are not free radicals per se but have oxidizing effects that contribute to
oxidant stress [Cai and Harrison, 2000].
Reactive oxygen species (ROS) play an important role in many cardiovascular
pathologies involving inflammatory processes, including atherosclerosis. Several
pathogenic effects of increased ROS production have been identified. These include the
oxidation of core lipids of lipoproteins and cell membranes which then modify
apolipoproteins and other proteins, leading to their recognition by scavenger receptors.
Similar modifications also influence DNA binding of regulatory proteins in the nucleus.
6

Exposure of cells to ROS induces a local inflammatory response and the release of
cytokines and growth factors, such as tumor necrosis factor-a., interleukin1 �, and
interferon Y. These factors may then provide a positive feedback mechanism, for example
by stimulating ROS-producing enzymes. Although cells are normally well protected from
ROS by antioxidant defenses, including oxygen-radical scavenger enzymes, the rate of
ROS formation can exceed the local antioxidant defense capacity and thus induce oxidant
stress in arterial cells [Napoli et al, 2001 ].
Vascular smooth muscle cell (SMC) hyperplasia and hypertrophy are characteristic of
atherosclerotic, restenotic, and hypertensive vascular diseases [Ross, 1993]. The net
balance between proliferation and apoptosis determines the extent of SMC growth. ROS
can mediate phenotypes in vascular endothelial and smooth muscle cells that may be
considered both physiological and pathophysiological. Among these are growth,
apoptosis, and survival. A full understanding of how ROS regulate mitogenesis and
apoptosis in vascular smooth muscle and endothelial cells will permit the development of
novel strategies to modify or prevent vascular diseases in which these phenotypes
predominate [Irani, 2000].

7

II. OBJECTIVES AND HYPOTHESIS

Tissue factor is the primary initiator of clotting, both normal and pathologic, in a large
number of clinical settings and animal models [Osterud, 1997]. Tissue factor upregulation
in atherosclerotic plaque can lead to undesirable vascular thrombosis [Vallet, 2001].
Balloon angioplasty of arteries causes endothelial denudation and, as a consequence of
the exposure of the endothelium to the blood, provokes an instantaneous activation of
platelets and the coagulation cascade [Gasperetti, 1993 and Hamon, 1995]. Tissue factor
is rapidly induced in the arterial smooth muscle injured by this procedure [Marmur,
1993]. An increase in the generation of reactive oxygen species (ROS) by the cells of the
vascular wall has been observed at sites of balloon injury [Nunes, 1997]. Oxidative stress
might contribute to the increased expression of proatherosclerotic genes at sites of
vascular injury, including TF [Taubman, 1997]. Our group has recently reported that LPA
(a component of oxLDL present within the intima of atherosclerotic lesions) dramatically
induces TF expression in RASMCs and it has been reported that it can also induce ROS
release in RASMCs [Schmitz, 2002]. Little is known about the regulation of TF by LPA
in SMC which is a major player in the process of atherosclerosis. The objectives of this
study are to elucidate the signal transduction pathways involved in tissue factor induction
by LPA in SMC. Understanding the mechanism of LPA induction of TF in SMC could
contribute to proper understanding of atherosclerosis, thrombosis and restenosis after
vascular procedures.
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III. MATERIAL AND METHODS
MATERIALS:

LPA used in this study was (1 8:1) oleoyl LPA from Avanti Polar Lipids, Inc.
pertussis toxin, RO-31 , GO-6979, U731 22, U73343, PD-98059, UO-1 26, Chelerythrin
chloride, GF, Resveratrol, SB, Sp, BPB (4-bromophenol bromide), Aristolochic acid,
BAPTA-AM, and MAFP were from Biomol Research Laboratories Inc. Arachidonic
Acid, N-acetyl cysteine, sodium formate, desferoxamine, DPI, BEL (bromophenol
lactone), thapsigargin, Luminol, and HRP (horse reddish peroxidase) were from Sigma
Inc. MJ-33 was from Calbiochem Inc. 3H-arachidonic acid was purchased from American
Radiolabeled Chemical Inc. (ARC).
TISSUE CULTURE:

Rat Aorta smooth muscle cells (RASMCs) were prepared from explants of excised
aortas of rats as described previously [Brock et al., 1 985]. RASMCs between passages
7and 1 7 were used in these studies. Cells were maintained in Dulbecco's modified Eagle's
medium containing 1 0% fetal bovine serum. Cells were made quiescent by incubation in
serum-free Dulbecco's modified Eagle's medium for 48 h prior to the addition of LPA or
other agonists or drugs as described previously [Schecter et al., 1997 and Penn et al.,
1 999]. Human smooth muscle cells (HASMCs) were purchased from BioWhittaker, A
Camprex Company. HASMCs between passages 4 and 7 were used.

9

NORTHERN BLOT ANALYSIS FOR DETECTION OF RASMCS TF MRNA:

Total cellular RNA was isolated by using TRizol reagent (Gibco BRL.) according to
the manufacturer's instructions. Total RNA (5-6 µg) was subjected to denaturing
electrophoresis in formaldehyde/agarose gels. RNA was blotted onto Hybond™-N; nylon
(Amersham) membranes and hybridized with radiolabeled cDNA probes [Virca et al.,
1990]. A 685-bp

EcoRI

fragment of rat TF cDNA (GenBank™ accession number

U0761 9) was a gift from Dr. Mark B. Taubman (Mount Sinai School of Medicine, New
York) and was used to detect TF mRNA, whereas glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA was used as an internal control.
NORTHERN BLOT ANALYSIS FOR DETECTION OF RASMCS EGR-1 AND
HASMCS TF MRNA:

Total cellular RNA was isolated by using TRizol reagent (Gibco BRL.) according to
the manufacturer's instructions. RNA samples (8 µg per lane) were separated by
electrophoresis through 1.2% agarose gels after denaturation of the RNA with glyoxal and
dimethylsulfoxide [Morawietz et al., 1999]. RNA was transferred with 20x SSC buffer to
Hybond-N nylon membranes (Amersham Life Science Inc). RNA was then hybridized
with radiolabeled cDNA probes (641 bp EcoRI fragment of human TF cDNA or 1 .5 kb of
mouse Egr-1 ) in: 1 mol/L NaCl, 1 % SDS, 10% dextran sulfate, and 100 µg/mL
denatured salmon sperm DNA at 65 ° C for 16 hours. The membranes were washed twice
for 15 minutes with 2xSSC, 0.1 % SDS at 60° C and once for 15 minutes with 0.2xSSC,
0. 1 % SDS at 55 °C.
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ADENOVIRUS CONSTRUCTS AND ADENOVIRAL INFECTION OF RASMCS:

Adenoviruses encoding mouse PKC isotypes (6, c, or t) were constructed as
previously described [Ohba et al., 1998 and Matsumoto et al., 2001]. The adenoviral
vectors were amplified in 293 cells to obtain a high titre of the virus before infecting
RASMCs. The cells were infected by vectors expressing the following proteins : Lac-Z
(control), wild type PKC e (PKC e -wt), kinase deficient PKC e (PKC e-kd), wild type
PKC

o (PKC o-wt), dominant negative PKC o (PKC o-dn), PKC t (PKC t-wt), and

dominant negative PKC t (PKC t-dn) for 24 h. the cells were then starved for 48 hours
and the stimulated by LPA for 1.5 h or unstimulated.
WESTERN BLOT ANALYSIS:

Total cellular proteins were obtained from RASMCs grown in 100-mm dishes. At the
end of each incubation, cell lysates were washed twice with PBS. Combined floating and
attached cells were lysed by sonication for 20 s on ice in Westem blot lysis buffer
(50 mM Tris-HCl, pH 6.8, 8 M urea, 5% J-mercaptoethanol, 2% SDS, and protease
inhibitors). After addition of 4x SDS sample buffer and incubation at 65 °C for 15 min,
samples were subjected to SDS-polyacrylamide gel 10% electrophoresis and transferred
to a polyvinylidene fluoride membrane (Immobilon-P, Millipore). The membranes were
then probed with antibodies against Egr-1 (Cl9), CREB, P-CREB, MEK, and P-MEK
(Snta Cruz) followed by a 1 :3000 dilution of a peroxidase-labeled secondry antibody. The
signal was visualized by ECL-Plus (Amersham Biosciences) as described previously [Xu
et al., 1999].
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ELECTROPHORETIC MOBILITY SHIFf ASSAYS:

Cell lysates were prepared from from RASMCs grown in 100-mm dishes. At the end
of each incubation, cell lysates were washed twice with PBS. Combined floating and
attached cells were lysed by sonication for 20 s on ice in luciferase assay lysis buffer
(Promega). Oligonucleotides containing a prototypic Sp1 site, an AP-1 site, and NFKB
site were obtained from Promega Corp. An oligonucleotide containing a prototypic EGR1 site was obtained from Operon Technologies (Alameda, CA). Oligonucleotides were
radiolabeled using [32P]dCTP (Amersham Corp.) as described [Oeth et al., 1994]. Gel
shift assays were performed as follows: cell lysates (4-5 µg) were incubated with
radiolabeled DNA probes (about l Ong; 1 )(106 cpm) for 20 min at room temperature in a
20-µl binding reaction containing 20 mM Hepes, pH 7.9, 50 mM KCl, 0.5 mM EDTA,
5% glycerol, 1 mM dithiothreitol, 1 mg/ml bovine serum albumin, 0.1% Nonidet P-40,
and 12.5 µg/ml poly (dl-dC). Protein-DNA complexes were separated from free DNA
probe by electrophoresis through 6% nondenaturing acrylamide gels (Novex, San Diego,
CA) in 0.5 xTris borate-EDTA. For competition and antibody supershift experiments,
binding reactions were incubated with unlabeled double-stranded oligonucleotides (50
molar excess) or monospecific antibodies for 20 min before the addition of the
radiolabeled oligonucleotide. Anti-EGR-1 (C19),anti-SRF, and anti CREB antibodies
were obtained from Santa Cruz Biotechnology, (Santa Cruz, CA).
TRANSIENT TRANSFECTION ASSAY:

RASMCs were cultured in 60-mm dish 24 h prior to transfections. SuperFect
reagent from Qiagen was used in transfeting the cells in accordance with the
12

manufacturer's recommendations. One set of RASMCs was transfected with a plasmid
containing the wild type TF promoter cloned upstream of the luciferase reporter gene
(5µg) [pTF (-258)]. Another set of cells was cotransfected with the same plasmid [pTF (258)] and another plasmid expressing Lacz (pcDNA3.l/LacZ) (5µg). A third set of cells
was cotransfected with pTF (-258) and another plasmid expressing Egrl (pSVKrox -24) (5
µg) which was kindly provided by P. Charnay [LeMaire et al., 1990]. Cells were starved
for 48 hours before assaying luciferase activity. Luciferase activity was determined using
the Luciferase Assay System (Promega) and ML2250 luminometer (Dynatech).
DELETION ANALYSIS AND FUNCTIONAL ANALYSIS OF THE EGR-1
PROMOTER:

A series of transfection studies have been conducted to determine the LPA primary
response regions in the Egrl promoter. According to the published rat Egrl promoter
sequence, a set of oligonucleotides have been synthesized as primers to clone a series of
Egrl promoter regions with selected deletions by PCR techniques using the rat genomic
DNA. These derivatives were cloned upstream of the luciferase reporter gene in the

plasmid pGL2. LPA responsiveness of the promoter region of the Egrl gene was
evaluated by transiently transfecting RASMCs with the deleted Egrl promoter constructs

.

(hooked to a luciferase reporter gene) and subsequently treating these cells with LPA
(25µM) for 3 hours after starving it for 48 hours. The construct pGL2/Egrl (-140/+21)
contains a luciferase reporter gene driven by the rat Egrl promoter fragment -140/+21
which have 2 SRE and 2 CRE areas. To perform Functional analysis of the Egr-1
promoter, We constructed a plasmid having the 2 SRE areas mutated [pGL2/Egrl (13

140/+21)dmSRE] and another plasmid having the 2 CRE areas mutated [pGL2/Egrl(140/+2 l)dmCRE]. RASMCs were transiently transfected by those constructs, starved for
48h and then either untreated or stimulated with LPA (25µM) for 3 hours.
ROS RELEASE DETECTION:

A variety of oxygen radicals, including superoxide anion and the hydroxyl radical,
as well as hydrogen peroxide are potential mediators of luminal-dependent
chemiluminescence Luminol (amino-2,3-dihydro-1,4-phthalazinedione) undergoes a
dioxygenation reaction in the presence of reactive oxygen species to yield a cyclic
peroxide that disintegrates to yield the electronically excited aminophthalate anion HRP
(horseradish peroxidase) is used to enhance the the chemiluminescence signal [Allen,
1982]. Rat Aorta smooth muscle cells (RASMC) were grown in Dulbecco's minimal
essential medium (DMEM) containing 10% fetal bovine serum. Cells were serum starved
for 24 hours in serum-free DMEM prior to use for experiments. ROS were detected by
the luminal and HRP-dependent chemiluminescence assay [Goldman et al, 1998].
Serum-starved cells were rinsed with PBS, trypsinized, suspended in Hanks balanced salt
solution (HBSS), and were washed twice with HBSS. Cells (1x106) were incubated in a
test tube (75x12 mm, Sarstedt no. 55.476) in 0.5 ml HBSS · containing 0.2% fatty acid
free BSA, 100 µM luminol, and 0.5 unit of HRP at 37 °C for 10 min. Cells were then
placed in the luminometer and LPA (25µM) was added at time 0. Chemiluminescence
was recorded immediately at 1 minute intervals.
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I
I.
., ' ACID {3H-AA) tRELEASED
FROM
DETERMINATION OF 3H-ARACHIDONIC

PRELABELED RASMC EXPOSED TO LYSOPHOSPHATIDIC ACID (LPA)�

To determine the effect of LPA on AA release in RASMC, cells were seeded into six
well culture plates at a density of 3 x 105 cells/well and grew them to 75% confluence.

..

Release of 3H-AA into the medium was determined as described previously [Tithof et al,
1998]. Briefly, the cells were labeled with 3H-AA for 24 h. Release of AA was
determined by incubating cells with compounds in Hank's Balanced Salt Solution with
0.1 % albumin to inhibit reacylation and metabolism of released AA. Therefore, the data
reflect cumulative deacylation from membrane phospholipids.
When the cells were 90 % confluent, release of

3

H-AA was determined after

exposure to LPA (25 µM) for 1 h. At the end of the incubation period, the medium was
collected

into

scintillation

vials

containing:

xylene,

2,5-diphenyloxazole,

polyoxyethylene, octyl phenol, Bis-MSB, and oleic acid. The radioactivity was
determined by scintillation counting. Radioactivity in the cellular fraction was also
determined, and 3H-AA release was expressed as a percentage of total cellular
radioactivity.
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IV. Results
INDUCTION OF TF MRNA BY LPA:

LPA significantly increased TF mRNA in quiescent RASMCs in a concentration
dependent manner with maximal accumulation at 25 to 50 µM LPA [Figure 1 (figures: 145 are located in the appendix)]. Maximal levels ofTF mRNA were observed at 1.5-2h of
LPA stimulation. The increased accumulation of TF mRNA induced by LPA was
transient and declined significantly between 4 and 8 hours (figure 2)_.
IDENTIFICATION OF THE TRANSCRIPTION FACTORS THAT BIND TO
THE RAT TF PROMOTER UPON INDUCTION BY LPA:

Our group's preliminary transfection data suggest that the region from -258 to +106
of the Rat TF promoter is important for the TF gene induction by oxLDL. This area
contains severaltranscription factor binding sites (two AP-1 sites, one NFrl3 site, four
Spl sites and one Egr-lsite). Electrophoretic mobility shift assays (EMSA) were used to
examine whether binding activities of the above mentioned transcription factors were
induced by LPA. Radiolabeled oligonucleotides containing the above mentioned sites in
the rat TF promoter were incubated with cell lysates from quiescent untreated cells or
cells treated with LPA for the indicate times. As shown in Fig.3 (C), at the Egr-1 site, in
addition to the slower migrating protein-DNA complex (complex I) which remains
unchanged during treatment, an increase in the signal intensity of another

faster

migrating protein-DNA complex (complex II) was induced by LPA. In contrast, no
detectable changes were observed in Spl, NFrl3, or Apt binding activities (figure 3 A, B,
D). The identity of this complex (complex II) was confirmed by using an antibody that
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specifically recognizes the transcription factor Egrl. The Egrl complex (complexll)
observed in LPA-stimulated cells [figure 4 (lane 2)] was abolished by pre-incubation of
the RASM cell lysate with the Egrl specific antibody, indicating that the induced band is
Egr-1 complex.
EGRl MRNA IS INDUCED BY LPA:

LPA (25 µM) significantly increased Egrl mRNA in quiescent RASMCs.
Maximal levels of Egrl mRNA were observed at about 35- 50 minutes of LPA
stimulation. The increased accumulation of TF mRNA induced by LPA was transient and
decreased significantly after about 3.5 hours (figure 5).
EGRl TRANSACTIVATES THE TF PROMOTER ACTIVITY:

RASMCs were trasfected with a plasmid containing the wild type TF promoter
cloned upstream of the luciferase reporter gene [pTF (-258)]. Another set of cells was
cotransfected with the same plasmid and another plasmid expressing Lacz
(pcDNA3.1/LacZ). A third set of cells was cotransfected with both pTF (-258) and
another plasmid expressing Egrl (pSVKrox-24). The results show increased fold of
luciferase activity in the cells cotransfected with both pTF/-258 and pSVKrox-24
compared to the other two sets indicating that Egr-1 transactivates the TF promoter,
suggesting that Egrl is a transcriptional activator ofthe TF gene in RASMCs (figure 6).
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INCREASED EGRl TRANSCRIPTIONAL BINDING ACTIVITY IS TRANSIENT
AND IS DUE TO DE NOVO PROTEIN SYNTHESIS:

To investigate if increased Egr-1 binding activity induced by LPA is due to de novo
protein synthesis or activation of pre-existing Egr-1 protein by post -translational
modification, levels of Egrl protein in cell lysates from quiescent and LPA-stimulated
RASMCs were assessed by western blotting using an Egrl-specific antibody. As shown
in figure 7, Egrl protein was not detectable in quiescent cells. However, Egrl protein
expression was transiently induced following stimulation with LPA and expression level
increased after about 35-50 minutes and then declined.
LOCALIZATION OF THE LPA-RESPONSIVE REGION IN THE EGRl
PROMOTER:

A series of transfection studies was conducted to determine the LPA primary response
regions in the Egrl promoter. Using the published mouse Egrl promoter sequence, a set
of oligonucleotides were synthesized as primers to clone a series of rat Egrl promoter
regions with selected deletions by PCR techniques using the rat genomic DNA. LPA
responsiveness of the promoter region of the Egrl gene was evaluated by transiently
transfecting RASMCs with the deleted Egrl promoter constructs which were inserted
upstream of the luciferase gene. The cells were subsequently treated with LPA (25µM)
for 3 hours after starvation for 48 hours. Four-fold induction by LPA was observed until
deletions reached -140 bp. Further deletion resulted in a significant loss of activity (figure
8, 9). Sequence analysis revealed that this area of the Egrl promoter contains two SRE
(serum response elements) and two CRE (cyclic AMP response elements) sites.
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FURTHER CHARACTERIZATION OF THE REGULATORY ELEMENTS IN
THE EGRl PROMOTER (SRE AND CRE ARE INVOLVED IN MEDIATING
LPA INDUCTION OF THE EGR-1 PROMOTER ACTIVATION:

Transcriptional regulation of gene expression is mediated through DNA binding
proteins, termed transcription factors. Response elements are the recognition sites of
certain transcription factors. Most of them are located within 1 kb from the
transcriptional start site. The Serum Response Element (SRE) present in the promoter
region of several genes, including Egr-1, requires the binding of SRF (serum response
factor) to activate expression of the gene downstream. [Lamb et al., 1996]. Another
response element in the Egr-1 promoter is the cyclic AMP response element (CRE) which
binds the transcription factor cyclic AMP response element binding protein (CREB)
[Silva et al, 1998].
EMSA (electrophoretic mobility shift assays) were performed by incubating 32 P
labeled oligonucleotides containing SRE and CRE sites with cell lysates from untreated
and LPA-stimulated RASMCs for various times. SRE binding activity was transiently
induced, peaked between 7 and 15 minutes and decreased to background level at about 30
minutes (figure 10). Similarly, CRE binding activity was' induced at about 10 minutes
(figure 11). To determine whether the binding of the cell lysates to these regions of the
Egrl promoter was specific, competition studies using 50- fold molar excess of unlabeled
SRE and CRE oligonucleotides were performed. Both SRF and CREB binding activities
were completely blocked (no induced complex was formed), indicating the specificity of
these bindings [Figure 12, 13 (lanes 5, 6)]. When radiolabeled oligonucleotides
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containing mutated SRE and mutated CRE were also incubated with cell lysates from
untreated and LPA-stimulated RASMCs for 15 and 10 minutes respectively. As shown in
Figure 12 and 13, Both mutated SRE and CRE sites failed to bind to corresponding
transcriptional factor confiming again the specificities of these binding activities observed
with wild type SRE and CRE. Further confirmation was achieved by using antibodies that
specifically recognize SRF and CREB. The protein-DNA complexes observed using
LPA-stimulated cells were supershifted by pre-incubation of the RASMC lysates with
these specific antibodies (fig1 2, 13).
FUNCTIONAL ANALYSIS OF THE EGRl PROMOTER CONFIRMED THE
INVOLVEMENT OF SRE AND CRE IN TURNING ON THE EGRl PROMOTER
BY LPA:

The construct pGL2/Egrl (-140/+21) contains a luciferase reporter gene driven by
the fully active rat Egrl promoter fragment -140/+21 which contains two SRE and two
CRE sites. We also constructed a plasmid having the two SRE sites mutated [pGL2/Egrl
(-140/+21) dmSRE] and another plasmid having the two CRE sites mutated
[pGL2/Egrl (-140/+21) dmCRE]. RASMCs were transiently transfected with those
constructs, starved for 48h and then either untreated or stimulated with LPA (25µM) for 3
hours. The results revealed that the double SRE and double CRE mutations reduced the
LPA induction of the Egrl promoter from 2.71 -fold to 1.1 7-fold and 1.11-fold
respectively (figure 14). These data together with the EMSA results indicates that both
SRE and CRE sites are required for mediating LPA-induction of Egr-1 which ultimately
regulate TF expression.
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PERTUSSIS TOXIN SENSITIVE G-PROTEIN, PKC, PKD, AND MAPK ARE
INVOLVED IN LPA-INDUCED TF AND EGRl SIGNALING PATHWAYS IN
RASMCS:

Several LPA receptors have been cloned and all ofthem have been identified as G
protein coupled receptors [Goetzl and An, 1998].To define the intracellular signaling
pathways involved in LPA-induced TF gene expression, RASMCs were preincubated
with the following drugs: pertussis toxin (Goo. inhibitor), UO-126, PD98059 (MAPK
inhibitors), SB-203580 (p38 inhibitor), GF-109, RO-31, chelerethrine chloride (pan-PKC
inhibitors),GO-6976 (a, (3 PKC inhibitor), Sp-600125 (JNK inhibitor), U-73122 (PLC
inhibitor), U73343 (negative control for U73122) and Resveratrol (PKD inhibitor).
Northern blot analyses revealed that LPA-induction of TF and Egrl mRNA accumulation
were blocked by PTX (Goo. inhibitor), indicating the involvement of a PTX-sensitive G
protein (Goo.) in the signaling pathway mediating LPA induction of TF and Egrl gene
expression. It was also found that LPA-induced TF and Egrl mRNA accumulation were
blocked in the cells pretreated with UO-126, PD98059 (MAPK inhibitors), GF-109, RO31, chelerethrine chloride (PKC inhibitors) and Resveratrol (PKD inhibitor) ,whereas,
they were not blocked by GO6976, SB-203580 (p38 inhibitor), Sp- 600125 (JNK
inhibitor) and U73343, {PLC inhibitor). These results suggest that MAPK, PKC and PKD
are involved in the signaling pathway of LPA-induced TF and Egrl gene expression
whereas PKC a, (3, p38, JNK and PLC are not involved (figures 15-18).
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PKCc IS INVOLVED IN LPA-INDUCTION OF TF MRNA EXPRESSION:

The above mentioned data suggest that some PKC isofonns (except for a, {j) are
involved in the signaling pathway of LPA-induced TF and Egrl mRNA expression. PKC
exists as a family composed of at least 10 isofonns. They are classified into three major
groups [conventional PKC isofonns (a, /jl, (fl, and 'Y), novel PKC isofonns

(o, e, r,, and

8) and atypical PKC isofonns (t and A) (Chiu and Rozengurt, 2001). The possible roles of

o, e , and t isofonns on LPA induction of TF m.RNA expression in RASMS have been
examined. An adenovirus vector system which allows high expression of the genes
encoding for these proteins in almost all the cells infected for at least 24 hours (kindly
provided by T. Kuroki) was used. RASMCs were infected by vectors expressing the
following proteins : Lac-Z (control), wild type PKC e (PKC e-wt), kinase deficient PKC e
(PKC e-kd), wild type PKC o (PKC o-wt), dominant negative PKC o (PKC o-dn), PKC t
(PKC t-wt), and dominant negative PKC t (PKC t-dn) for 24 h. the cells were starved for
48 hours and then stimulated by LPA for 1.5 h or unstimulated. Total RNA was harvested
and Northern blot analyses were performed. TF mRNA was only blocked in cells infected
with the adenovirus expressing kinase deficient PKC f suggesting that PKC f is involved
in LPA-induced TF m.RNA expression, whereas, PKC o and PKC t are not involved in
this signaling pathway (figures 19, 20).
LPA STIMULATES ROS RELEASE IN RASMCS:

Reactive oxygen species (ROS) in specified amounts play an important role in
normal metabolic and signalling processes. However, excess ROS can cause severe
cardiovascular damage. ROS cause various types of damage to ion channels and pumps
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and this damage is associated with vascular diseases such as atherosclerosis and
hypertension (Walia et al, 2003). To determine whether LPA increases ROS release in
RASMCs, serum-starved RASMCs were incubated with luminal (100 µM) and HRP (see
material and methods for details). Low chemiluminescence was detected in the absence of
LPA. Addition of LPA (25µM) caused a rapid and marked increase in the
chemiluminescence signal within a couple of minutes to return to the basal level after
about 5 to 6 hours (figure 21). To determine if the chemiluminescence signal was
generated from ROS, cells were pre-treated with N-acetyl cysteine (a general antioxidant)
in a concentration of 10 mM for 30 minutes and then treated with LP A (25µM). Figure 21
shows that NAC diminishes the LPA-stimulated chemiluminescence signal, indicating
).

that the chemiluminescence signal is a valid measure for ROS release. These results
•

.1 ..

indicate that LPA stimulates ROS release in RASMCs.

'

ANTIOXIOXIDANTS BLOCK LPA INDUCTION OF TF MRNA:
'

The above mentioned data indicates that LP A induces TF mRNA expression and
at the same time stimulates ROS release. To determine whether LP A-induced ROS
release is also involved in TF mRNA induction, quiescent RASMCs were stimulated with
LPA (25 µM) for 1.5 h alone or after preincubation with the following antioxidants:
,. F. (specific
• blocker for free hydroxyl radicals release)] in a
sodium formate [Na
concentration of 100 mM for 24 h, N-acetyl cysteine [NAC (general antioxidants)] in a
concentration of 10 mM for 30 min., desferoxamine mesylate (hydrogen peroxide release
blocker) in a concentration of 50 mM for 30 min., and DPI [diphenyleneiodonium
chloride (specific blocker for free oxygen radical release)] in a concentration of 25 µM
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for 30 min. Northern blot analysis revealed that LPA-induction of TF mRNA was
blocked in the cells pre-treated with sodium formate, NAC and DPI suggesting that ROS
is involved in LPA induction ofTF mRNA (figure 22).
'
MAPK IS INVOLVED, BUT, PTX AND PKC ARE NOT INVOLVED IN fLPA

INDUCTION OF ROS RELEASE IN RASMCS:
In the above mentioned data, PTX, PKC, and MAPK were shown to be involved
in LPA-induction of TF mRNA. ROS release was measured in quiescent RASMCs after
stimulation with LPA (25µM) alone or after pretreatment with PTX (1 20ng/ml) for 16 h,
GF (lOµM), or UO1 26 (lOµM) (for 30 minutes each) to determine if the same G
proteins-coupled receptors signaling pathway (involved in LPA-induced TF mRNA) is
also involved in LPA-stimulated ROS release. As shown in figures 23, 24, and 25, PTX
(Gai inhibitor) and GF (pan-PKC inhibitor) failed to block this induction. Only UO1 26
(MAPK inhibitor) was effective. These data suggests that LPA-induction of ROS release
may involve an alternative signaling pathway which does not involve PTX-sensitive G
protein.
LPA STIMULATES AA RELEASE IN RASMCS:
Arachidonic acid (AA) is a polyunsaturated fatty acid present in cell membranes that
modulates diverse physiologic and pathologic responses. These effects are primarily
mediated by its metabolic products. Their effects, which depend on the nature of
compounds, principally concern inflammation and thromboregulation (Marcus, 1 994 ). It
is well known that several transduction pathways are activated by LPA including
arachidonic acid release (Moolenaar, 1995). To determine whether LPA increases AA
24

release in RASMCs, the cells were labeled with 3H-AA for 24 h. Release of AA was
determined by incubating cells with LPA (25 µM) in Hank's Balanced Salt Solution with
0.1 % albumin to inhibit reacylation and metabolism of released AA. When the cells were
90 % confluent, release of

3

H-AA was determined after exposure to LPA (25µM) for 1

h. At the end of the incubation period, the medium was collected into scintillation vials
and the radioactivity was determined by scintillation counting. Radioactivity in the
cellular fraction was also determined, and 3 H-AA release was expressed as a percentage
I • for the release of AA in
of total cellular radioactivity. Figure 26 shows a time course

RASMCs upon stimulation by LPA.
AA INDUCES TF MRNA:

AA is known to enhance the TF expression in mononuclear cells (Cadroy et al,
•
1998). To determine whether AA induces TF mRNA in RASMCs, quiescent IRASMCs

..

were stimulated with AA (I OµM) for different periods of time. Northern blot analysis was
performed. Maximal levels of TF mRNA were observed after about 1.5 h of LPA
stimulation. The increased accumulation of TF mRNA induced by LPA was transient and
decreased to basal level in 8 hours (figure 27).
AA STIMULATES ROS RELEASE IN RASMCS:

It was reported that AA may play an essential part in activation of the enzyme
NADPH oxidase, which is responsible for the generation of superoxide anion by
neutrophils (Dana et al, 1994; Henderson et al, 1993; and Badwey et al, 1981). To
determine whether AA increases ROS release in RASMCs, serum-starved RASMCs were
incubated with luminol and HRP. Low chemiluminescence was detected in the absence of
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AA. Addition of AA (lOµM) caused ·a rapid increase in the chemiluminescence signal
within a couple of minutes. (figure 28). To determine if the chemiluminescence signal
was generated from ROS, cells were pre-treated with N-acetyl cysteine (a general
antioxidant) and then treated with AA (l0µM). Figure 28 shows that NAC diminished the
AA-stimulated chemiluminescence signal. Together, these results indicate that AA can
stimulate ROS release in RASMCs.
ANTIOXIOXIDANTS BLOCK AA INDUCTION OF TF MRNA IN RASMCS:

The data presented above indicates that AA induces TF mRNA and at the same
time stimulates ROS release in RASMCs. To determine whether AA-induced ROS
release is also involved in TF mRNA induction, quiescent RASMCs were stimulated with
AA (50µM) for 1.5 h alone or after pre-treatment with the following antioxidants: sodium
formate [Na F. (specific blocker for free hydroxyl radicals release)] in a concentration of
lO0mM for 24h, N-acetyl cysteine [NAC (general antioxidants)] in a concentration of 10
mM for 30 min., desferoxamine mesylate (hydrogen peroxide release blocker) in a
concentration of 50 mM for 30 min., and DPI [ diphenyleneiodonium chloride (specific
blocker for free oxygen radical release)] in a concentration of 25 µM for 30 min.
Northern blot analysis revealed that AA-induction of TF mRNA was blocked in the cells
pre-treated with sodium formate, and DPI, suggesting that ROS is involved in AA
induction of TF mRNA (figure 29).
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PHOSPHOLIPASE A2 (PLA2) IS INVOLVED IN RELEASING AA FROM .
MEMBRANE PHOSPHOLIPIDS:
PLA2 cleaves phospholipids at the sn-2 position to produce AA (Van Corven et al,
1989). Several different isoforms of PLA2 have been described [Murakami and Kudo,
2002] . To investigate whether PLA2 is involved in releasing AA from membrane
phospholipids in RASMCs upon stimulation by LPA, quiescent RASMCs were
stimulated with LPA (25 µM) for 1.5 h alone or after pretreatment with the following
PLA2 inhibitors: MAFP (10 µM), ARA (aristolochic acid, 10 µM), BPB (10 µM), Bel (10
µM), and MJ33 (10 µM), each for 30 minutes. It was found that LPA-induction of TF
mRNA was blocked in the cells pre-treated with ARA, Bel, and MJ 33, suggesting that at
least some of PLA2 isoforms are involved (figure 30). The same PLA2 inhibitors also
blocked ROS release in RASMCs (figure 31, 32, 33) suggesting that LPA-induction of
ROS release in RASMCs involves PLA2 -mediated AA release.
ANTIOXIDANTS DO NOT BLOCK LP A-INDUCTION OF MAPK SUGGESTING
THAT LPA-INDUCED ROS RELEASE IS DOWNSTREAM OF MAPK
INDUCTION IN RASMCS:
The above mentioned data (figure 25) suggests that MAPK is involved in LPA
induction of ROS release in RASMCS. To further confirm that MAPK acts upstream of
ROS, quiescent RASMCs were stimulated with LPA (25µM) for 3 minutes alone or after
preincubation with the following antioxidants: sodium formate [Na F. (specific blocker
for free hydroxyl radicals release)] in a concentration of lOOmM for 24h, N-acetyl
cysteine [NAC (general antioxidants)] in a concentration of 10 mM for 30 mm.,
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desferoxamine mesylate (hydrogen peroxide release blocker) in a concentration of 50 mM
for 30 min., and DPI [diphenyleneiodonium chloride (specific blocker for free oxygen
radical release)] in a concentration of 25 µM for 30 min. Cell lysates were collected and
Western blot analysis was performed. Figure 34 shows that the anti-oxidants, which were
shown to block ROS production, do not block LPA-induction of MAPK suggesting that
LPA-induced ROS acts downstream ofLPA-induced MAPK activation or independent of
MAPK activation.
U0126 BLOCKS AA-INDUCTION OF ROS RELEASE CONFIRMING THAT
ROS ACTS DOWNSTREAM OF MAPK:

Serum-starved RASMCs were incubated with luminol and HRP. They were then
stimulated with AA (lOµM) alone or after pre-incubation with U0 126 (lOµM) for 30
minutes. Addition of AA (l0µM) caused a rapid increase in the chemiluminescence
signal within a couple of minutes. U01 26 pretreatment diminished AA-stimulated
chemiluminescence signal (figure 35) confirming that MAPK mediates AA-induction of
ROS release.

CALCIUM MOBILIZATION IS INVOLVED IN LPA-INDUCTION OF TF
EXPRESSION:

It is well known that LPA induces calcium mobilization (Jalink et al., 1995 and
AN et al., 1 998). A previous study also indicated that calcium is required for ROS release
in kerationocytes (Goldman et al., 1998). To determine whether calcium mobilization is
involved in the LPA-induced TF mRNA pathway, quiescent RASMCs were stimulated
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with Thapsigargin alone [endoplasmic reticulum Ca ATPase inhibitor (10 µM for 1 .5 h)],
with LPA alone (25 µM for 1.5 h) or after preincubation with BAPTA-AM [intracellular
calcium chelator (40 µM for 30 minutes)]. Northern blot analysis was performed. The
results show that thapsigargin alone was able to induce TF mRNA. At the same time,
BAPTA-AM was able to block LPA-induced TF mRNA suggesting that calcium
mobilization is involved in induction of TF mRNA by LPA (figure 36).
CALCIUM MOBILIZATION IS INVOLVED IN LPA-INDUCTION OF ROS
RELEASE:

To determine whether calcium mobilization is also involved in LPA-induced ROS
release, serum-starved RASMCs were incubated with luminol and HRP. They were then
stimulated with LPA (25µM) alone or after pre-incubation with BAPTA-AM (40µM) for
30 minutes. Addition of LPA (25 µM) caused a rapid increase in the chemiluminescence
signal within a couple of minutes. BAPTA-AM pretreatment diminished the LPA
stimulated chemiluminescence signal (figure 37), suggesting a role for calcium
mobilization in LPA-induction of ROS release.
CALCIUM MOBILIZATION IS ALSO INVOLVED IN BOTH AA-INDUCED TF
MRNA AND AA-INDUCED ROS RELEASE :

We also determined whether calcium mobilization is involved in AA-induction of
TF mRNA and ROS release. The same previous 2 experiments (determining the relation
between calcium mobilization and both TF mRNA and ROS release induction by LPA)
were repeated exchanging AA (50µM) for LPA (25µM). Similar results were observed,
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suggesting that calcium mobilization is also involved in AA-induction of TF mRNA and
ROS release in RASMCs (figure 38, 39).
USE OF HUMAN AORTA SMOOTH MUSCLE CELLS (HASMCS):

Northern blot analyses were performed using Quiescent HASMCs to see whether
the results obtained by using RASMCs can be reproduced in human cells. LPA
significantly increased TF mRNA in quiescent HASMCs in a concentration dependent
manner with maximal accumulation at SµM LPA (compared to 25-S0µM in RASMCs),
indicating that HASMCs are more sensitive to LPA (compare figure I and figure 39). The
results also indicate that responses to pertussis toxin and kinases inhibitors were similar,
whereas the human cells were responding mainly to antioxidants blocking the release of
free oxygen radicals (figures 40-45) (RASMCs responded also to antioxidants that block
the release of free hydroxyl radicals).
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V. DISCUSSION
Tissue Factor is the principal initiator of blood coagulation [Morrissey, 1997].
Upregulation of intravascular TF occurs in many models of inflammation and stress, and
its upregulation is important in pathologic thrombotic events [Kibbe et al., 2003]. LPA is
a component of oxLDL which has been shown to accumulate in human atherosclerotic
plaques [Seiss et al., 1999]. Our group has recently reported that LPA markedly induces
TF mRNA, TF protein , and TF surface activity in RASMCs [Cui et al., 2003]. It has also
been reported that LPA induces ROS release in RASMCs [Schmitz, 2002]. The
generation of ROS, which act as a signaling molecule in the vascular system, is enhanced
in response to injury and has been associated with a procoagulant state and the
progression of atherosclerotic disease [Berk, 1999; Kunsch and Medford, 1999; and Ruef
et al., 1999]. The results of our study provide a link between these observations and
contribute to dissecting the relevant signaling pathways involved.
The importance of oxidized LDL (OxLDL) in atherogenesis is currently well
appreciated [Kita et al., 2001]. LPA is formed during mild oxidation of LDL and it was
reported to be a major component of both the lipid core and the intima of atherosclerotic
lesions [Seiss et al., 1999]. LPA may play a role in the early phase of atherosclerosis by
inducing monocyte adhesion to the vascular endothelium, as well as in the late phase by
triggering platelet activation and intra-arterial thrombus formation upon rupture of the
atherosclerotic plaque. Moreover, LPA, by stimulating the proliferation of fibroblasts
and by enhancing the survival of inflammatory cells, is likely to play a central role in the
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excessive fibro-proliferative and inflammatory response to vascular injury that
characterizes the progression of atherosclerosis. Furthermore, LPA can cause the
phenotypic de-differentiation of medial smooth muscle cells that leads to the formation of
the neointima [reviewed in Seiss, 2002]. Our study demonstrates that LPA significantly
increases TF mRNA in both RASMCs and HASMCs. These data indicate another
important aspect of the athero- and thrombogenic actions of lysophosphatidic acid.
A recent study of our group indicated that LPA-induced increase in TF mRNA 1s
controlled at the transcriptional level [Cui et al., 2003]. The transcriptional regulation of
TF expression appears to be both cell type-specific and stimulus-specific [ reviewed in
Bavendiek et al., 2002 and Mackmam, 1997]. Functional studies of the human TF
promoter in various cell types identified two promoter regions implicated in TF gene
expression. The first region, termed the LPS-response element (LRE), contains two AP-1
(activator protein-I ) and one NF-KB (nuclear factor KB)-like binding sites. The LRE
mediates inducibility of the TF promoter in response to pro-inflammatory stimuli (e.g.
IL-1/3 and TNFa), LPS, and PMA. The second region, the serum response region (SRR),
contains three Egr-1 binding sites. This region mediates the induction of TF gene
expression via Egr-1 in response to serum, PMA, shear stress, LDL, hypoxia, vascular
endothelial growth factor, and LPS. A distal enhancer (-227 to -1 72) containing two AP-1
sites and an NF-KB site mediates induction of the human TF promoter in monocytic cells
and endothelial cells. Similarly, two AP-1 sites (-220 to -200) regulate induction of the
murine TF promoter in fibroblast-like cells. Proximal enhancers in the human (-109 to 59) and rat (-103 to -80) TF promoters containing Egr-1 and Sp1 sites mediate induction
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in epithelial-like cells and vascular smooth muscle cells, respectively. Our results indicate
that LPA significantly induces TF and Egr-1 mRNA in RASMCs. Our western blot
analysis and gel-shift results indicate that LPA induces immediate and de novo Egr-1
mRNA and protein synthesis. Importantly, our data demonstrate that LPA induces the
binding activity of Egr-1 to the TF promoter. These results suggest that LPA-induction

..

of TF gene expression in RASMCs is mediated by the transcription factor Egr-1.
Egr-1 is a ubiquitous transcription factor that participates in a wide range of
physiological and pathophysiological processes [Gashler and Sukhatme, 1995]. The Egr1 promoter contains many regulatory elements, including two Sp 1 sites, five serum
response elements (SREs) with adjacent Ets-like motifs, two cAMP response elements
(CREs). The SREs in the Egr-1 promoter have been extensively studied. The distal SREs
are critical for induction of Egr-1 by GH (growth hormone), PDGF (platelet- derived
growth factor), GM-CSF (granulocyte macrophage colony-stimulating factor), urea, and
stress. The proximal CRE is required for stimulation by GM-CSF and the distal CRE is
,, (p38/stess-activated protein kinases) [reviewed in
required for stimulation by SAPKs
Duan et al., 2002]. To localize the LPA-responsive region in the Egr-1 promoter, a
deletion analysis was performed. Our results indicated that the fold induction by LPA
was relatively constant until deletions reached -140 bp. Further deletion resulted in a
significant loss of activity, suggesting that the LPA response region is located within 140bp. This area contains two SREs and two CREs. EMSA and super shift experiments
indicated that specific SRF and CREB binding activities to the SRE and CRE of Egr-1
promoter were induced by LPA. Functional analysis of the Egr-1 promoter confirmed the
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EMSA results and indicated that both SREs and CREs are responsible for LPA induction
of the Egr-1 promoter activation in RASMCs.
In vascular tissues, LPA binds to members of a family of G protein-coupled
receptors, EDG (endothelial differentiation genes). Eight distinct subtypes of EDG
receptors have been identified in mammalian cells. EDG-2 receptors are activated by
LPA and the responses mediated by this subtype are blocked by pertussis toxin [Kou et
al., 2002]. LPA was shown to sequentially activate PKC and MAPK in mesangial cells
[Coy et al., 2002]. LPA was also reported to stimulate protein kinase C (PKC) in a
pertussis toxin sensitive pathway in vascular smooth muscle cells [Seewald et al., 1 999].
PKC- zeta was shown to mediate angiotensin II-induced and platelet derived growth
factor (PDGF)-induced MAP kinase activation in vascular smooth muscle cells and Rat
fibroblasts respectively [Liao et al., 1 997 and van Dijk et al., 1997]. PKC -epsilon was
also reported to activate MAPK in cat oesophagus smooth muscle cells upon induction by
C2-ceramide [Shin et al., 2002]. Xuereb et al., 2000 reported that they were able to
inhibit LPS-induced tissue factor synthesis in human vascular smooth muscle cells by
disruption of ERK kinases and PKC signaling pathways. A group of kinases with PKC
like functional structures has been described. This kinase family consists of PKCµ, its
mouse homologue termed PKD [Johannes et al., 1994 and Valverde et al., 1994]. These
kinases share structural homology to PKCs with respect to the catalytic domain and to the
presence of amino-terminal cysteine fingers, defining the structural basis for lipid
binding. PKCµ/PKD differs from PKC isozymes by an acidic domain, a PH domain
within the regulatory region and the lack of a typical pseudo-substrate site [Gschwendt et
al., 1997 and Gibson et al., 1994]. PKCµ/PKD activation occurs through several
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mediators via a PKC-dependent pathway [Zugaza et al., 1996]. PKC-epsilon was reported
to colocalize with, phosphorylates, and activates PKC-µ in HEK293 cells [Brandlin et al.,
2002]. In another study [Hausser et al., 2001], PKC-µ was shown to selectively activate
the MAPK pathway. A previous study indicates that LPA induces expression of the Egr-1
transcription factor in mesangial cells. This induction was pertussis toxin sensitive and
was blocked by a MAPK inhibitor. Oxidized phospholipids were shown to stimulate TF
expression in human endothelial cells via activation of PKC/ERK/Egr-1 and calcium
[Bochkov et al., 2002]. Our results also show that Pertussis toxin sensitive G-protein
(Gai), PKC-c, PKD, and MAPK are involved in LPA-induction of TF and Egrl mRNA.
Taken together, our results (together with the published data) suggest a signaling pathway
in RASMCs starting by LPA activating Gai protein which in tum activate PKC- epsilon.
PKC-epsilon then activates PKC-µ / PKD which phosphorylates MAPK. Activated
MAPK induces Egr-1 which is involved in turning on TF gene in the nucleus (figure 46).
Many cells which comprise the vasculature, generate reactive oxygen species (ROS)
[Irani, 2000]. Oxidative stress is a term used to describe an imbalance between the
production and destruction of reactive oxygen species (ROS), thereby leading to cellular
and tissue injury [Rice-Evans and Burdon, 1994]. The common risk factors for
atherosclerosis increase production of reactive oxygen species (ROS) by endothelial,
vascular smooth muscle, and adventitial cells [Harrison et al., 2003]. The damage
inflicted by ROS on cellular and extra-cellular targets such as membrane lipids, proteins,
and DNA clearly contribute to tissue and organ dysfunction in many pathological states.
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ROS has been identified as signaling molecules in a variety of cell types,
including smooth muscle cells and other vascular cells. In particular, the oxidation of
low-density lipoproteins (LDL) in the vascular wall is widely accepted to play a
fundamental role in the pathogenesis of atherosclerosis [Shihabi et al., 2002].
Lysophosphatidic acid (LPA) is formed during mild oxidation of LDL and is the active
compound in mildly oxidized LDL and minimally modified LDL [Siess et al., 1999].
Because of the importance of both LPA and ROS in vascular disease, we were interested
in studying their interactions and relations at the molecular level. LP A was reported to
stimulate ROS production in Hela cells [Chen et al., 1995]. Our results indicate that LPA
induces ROS release in RASMCs, suggesting an important role for ROS in the athero
and thrombogenic actions of lysophosphatidic acid.
Increased ROS production is observed at sites of vascular injury and has been
related to the development of restenosis/atherosclerosis [Berk, 1999]. Moreover, the
enhanced generation of ROS promotes a procoagulant state [Ruef, 1 999]. A role of ROS
in the control of coagulation has been suggested, and the key activator of the extrinsic
coagulation cascade, tissue factor (TF), has been shown to be modulated by ROS in
several cell types, including vascular cells [Herkert and Gorlach, 2002]. Our results
indicate that LPA-induction of TF mRNA was blocked by antioxidants suggesting a role
for ROS in the control of LPA-induction of TF expression in RASMCs. To further
elucidate the signaling pathways involved in ROS-mediated LP A-induction of TF gene
expression in RASMCs, ROS release was measured in quiescent RASMCs after
stimulation with LPA (25µM) alone or after pretreatment with PTX (Goo inhibitor), GF
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(PKC inhibitor), and UO126 (MAPK inhibitor) to determine if the same G proteins
coupled receptors signaling pathway (involved in LPA-induced TF mRNA) is also
involved in LPA-stimu_lated ROS release. Our results indicate that PTX (Gai inhibitor)
and GF (pan-PKC inhibitor) failed to block this induction. In contrast, the MAPK
inhibitor, UO-126, blocked LPA-induction of ROS production. These data suggest that
LPA-induction of ROS release may involve an alternative signaling pathway which is
different from the Gai protein-coupled receptor pathway.
It is well known that several signaling pathways are activated by LPA including
calcium mobilization and AA release. It has been reported that LPA stimulates ROS
release in human keratinocytes by a pathway involving intracellular calcium release,
phospholipase A2 (PLA2) stimulation, and arachidonic acid (AA) release [reviewed in
Sekharam et al., 2000]. Arachidonic acid serves as precursor for the generation of
bioactive lipid mediators known as eicosanoids that include prostaglandins,
thromboxanes, and leukotrienes [Tithof et al., 1998]. Arachidonic acid metabolites are
important regulators of inflammation, blood coagulation, and thrombosis [Marcus, 1994;
Petrukhina and makarov, 1997]. Eicosanoids modulate physiologic processes in the
vessel wall contributing to atherosclerosis and thrombosis, including platelet aggregation,
control of vascular tone, and the local inflammatory response [Linton and Fazio, 2002].
Proliferation of vascular smooth muscle cells (VSMCs) is implicated in the pathogenesis
of primary atherosclerosis, and restenosis following interventional revascularization
procedures such as balloon angioplasty, arterial stenting, and by-pass surgery [Anderson
et al., 1997]. AA has been reported to induce smooth muscle cell proliferation and
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migration by releasing reactive oxygen species in rabbit cultured aortic smooth muscle
cells [Nishio and Watanabe, 1 997]. AA has also been reported to induce apoptosis in rat
glioma cells and human promyelocytic leukemia cells (HL-60) by accumulating reactive
oxygen species [Higuchi and Yoshimoto, 2002; Arita et al., 2001 ]. LTB4 [leukotriene B4
(an arachidonic acid metabolite)] induces ROS generation in Rat-2 fibroblasts,
neutophils, eosinophils, and other fibroblasts [reviewed in Woo et al., 2002]. AA was
shown to enhance tissue factor expression in mononuclear cells by the cyclo-oxygenase
pathway [Cardoy et al., 1 998]. Eicosanoids (AA metabolites) were also shown to enhance
LPS and TNF-a -evoked expression of monocyte TF [Eilertsen et al., 2003]. Our results
indicate that LPA stimulates rapid release of AA in RASMCs. These results also indicate
that AA stimulates ROS release and induces TF m.RNA, suggesting its involvement in
ROS -induction of TF expression in RASMCs upon stimulation by LPA.
Phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of
membrane glycerophospholipids to liberate arachidonic acid (AA). The same reaction
also produces lysophosholipids, which represent another class of lipid mediators. So far,

..

... 1 9 enzymes that possess PLA2 activity have been identified and cloned in
at . least
mammals [Kudo and Murakami, 2001]. The secretory PLA2 (sPLA2) family, in which
10 isozymes have been identified, consists of low-molecular weight, Ca2+-requiring
secretory enzymes that have been implicated in a number of biological processes, such as
modification of eicosanoid generation, inflammation, and host defense. The cytosolic
PLA2 (cPLA2) family consists of three enzymes, among which cPLA2alpha has been
paid much attention by researchers as an essential component of the initiation of AA
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metabolism. The activation of cPLA2alpha is tightly regulated by Ca2+ and
phosphorylation. The Ca2+-independent PLA2 (iPLA2) family contains two enzymes
and may play a major role in phospholipid remodeling. The platelet-activating factor
,J.
(PAF) acetylhydrolase (PAF-AH) family contains four enzymes that exhibit
unique

substrate specificity toward PAF and/or oxidized phospholipids. Degradation of these
bioactive phospholipids by PAF-AHs may lead to the termination of inflammatory
reaction and atherosclerosis [Kudo and Murakami, 2001].
Atherosclerosis can be regarded as a localized inflammation of the artery wall,
and plaque progression is substantially driven by inflammatory mediators. Lipoprotein
associated phospholipase A2 (Lp-PLA2) is a calcium-independent serine lipase that, in
plasma, is mostly associated with low density lipoprotein (LDL) particles. Its substrates
include platelet-aggregating factor (PAF), and the enzyme is widely referred to in the
literature as PAF acetylhydrolase. Oxidised LDL (formed under conditions of oxidative
stress, such as exist in the artery wall) contains a variety of lipid peroxidation products,
which are efficiently hydrolysed at the SN2 position by Lp-PLA2. The products are
oxidised fatty acids plus lyso-phosphatidylcholine (PC); both have a variety of
proinflammatory effects in many cell types, including monocyte. A proposed
proatherogenic mechanism for this enzyme is that associated Lp-PLA2, becomes oxidised
within the intima, providing a substrate for the enzyme. The resulting hydrolysis products
,, is associated with macrophage accumulation.
,/ CI
promote the chronic inflammation that
Macrophages also produce and secrete further Lp-PLA2, representing one of the positive
feedback mechanisms driving disease progression [Leach et al., 2001].
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LPA may be synthesized by cells either de novo from glucose through pathways
of lipid metabolism in the endoplasmic reticulum or through liberation of precursor
phospholipids and subsequent enzymatic conversions in membrane microvesicles
[Goetzl, 1 998; Jalink, 1 994; and Gaits, 1997]. PLD first converts phosphatidylcholine to
PA and PLA2 then hydrolyzes the sn-2 (sn-1) ester bond of PA to generate LPA.
Exogenous LPA can also induce PLA2 to generate LPA (positive feed back mechanism)
[Eder et al., 2000]. Our results demonstrate that LPA-induced TF mRNA was blocked in
the cells pre-treated with ARA, Bel, and MJ 33 (PLA2 inhibitors), suggesting that at least
some of PLA2 isoforms are involved in LPA-induced AA release. The same PLA2
inhibitors also blocked ROS release in RASMCs suggesting that LPA-induced ROS
release in RASMCs involves AA release by PLA2 .
LPA is known to activate arachidonic acid release, MAPK activation and calcium
I

mobilization [Sekharam et al., 2000]. AA and its metabolites are implicated in the control
of calcium homeostasis, including modulation of calcium release and calcium entry via
voltage-gated and nonvoltage-gated pathways by AA itself or by metabolites synthesized
via cyclooxygenase (COX), lipoxygenase (LOX), or mono-oxygenase (cytochrome P450,
MOX) pathways. In general, AA and its metabolites stimulate calcium mobilization [Liu
and Rittenhouse, 2000]. AA was shown to activate MAPK in vascular smooth muscle
cells [Kalyankrishna and Malik, 2003]. MAPK was also reported to induce ROS
generation in human lung endothelial cells and other cells [Parinandi et al., 2002 and Kroj
et al., 2003]. Increased intracellular calcium concentration was shown to induce TF
expression in vascular endothelial cells [Taubman et al., 1 993 and Wakita et al., 1994].
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Our results show that thapsigargin (intracellular calcium mobilization inducer) alone was
able to induce TF mRNA. At the same time, BAPTA-AM (intracellular calcium chelator)
· was able to block both LPA-induced TF mRNA and LPA-induced ROS release in
RASMCs. Our western blot results also show that antioxidants do not block LPA
induction of MAPK suggesting that LPA-induction of ROS release acts downstream of
MAPK activation in RASMCs. Taken together, these data show the diverse ways and
signaling mechanisms by which LPA can induce TF in RASMCs (figure 47). In one
pathway, LPA activates PLA2 which releases AA from the membrane phospholipids. AA
can then activate MAPK, ROS release, and calcium (all of them can induce TF). In
another pathway, LPA activates MAPK which induces ROS release inducing TF. LPA
can also induce ROS release to induce TF.
We used HASMCs to reproduce some of the mam experiments performed
initially in RASMCs. HASMCs are more expensive and more difficult to grow compared
to RASMCs. We were able to reproduce most of the important data we had in RASMCs,
including the induction of both· TF mRNA and ROS release by LPA and AA. These
results indicate that RASMCs still represent an authentic model for studying vascular
smooth muscle cell biology.
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VI. SUMMARY AND CONCLUSION
Lysophosphatidic acid (LPA) is a potent bioactive phospholipids with specific
and multiple effects on blood cells and cells of the vessel wall. LPA is a component of
oxidized low density lipoproteins (oxLDL) which has been shown to accumulate in
human atherosclerotic plaques. Tissue factor is the principal initiator of blood
coagulation. The active form of TF has been shown to be present in specimens of human
coronary artery in association both with acellular lipid areas and with macrophages and
smooth muscle cells, which suggests that TF plays a major role in determining plaque
thrombogenicity. The generation of ROS, which act as a signaling molecule in the
vascular system, is enhanced in response to injury and has been associated with a
procoagulant state and the progression of atherosclerotic disease.
Our group has recently reported that LPA markedly induces TF mRNA, TF
protein, and TF surface activity in RASMCs. It has also been reported that LPA inducees
ROS release in human keratinocytes. Little is known about the regulation of TF by LPA
in SMC which is a major player in the process of atherosclerosis. The present study
investigated the regulation of TF expression by LPA in RASMCs. Data generated by this
study demonstrate that LPA markedly induces TF expression in RASMCs and HASMCs.
The signaling pathways involved are multiple. One signaling pathway demonstrates that

LPA activates Gai protein which in turn activate PKC- epsilon that activates PKC-µ I

PKD which phosphorylates MAPK to induce Egr-1 that is involved in turning on TF gene
in the nucleus. Another pathway indicates that LPA activates PLA2 which releases AA
from the membrane phospholipids. AA can then activate MAPK, ROS release, and
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calcium (all of them can ·induce TF). In another pathway, LPA activates MAPK which
induces ROS release inducing TF. LPA can also induce ROS release to induce TF. Our
data suggest that elevated LPA have potential atherogenic and thrombogenic actions by
inducing TF expression an ROS release. Understanding the mechanisms involved could
provide new insights into atherosclerosis, thrombosis and restenosis after angioplasty. It
could also help in designing therapeutic strategies for these disease conditions.
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Fig.1. Induction of TF mRNA in response to LPA in
RASMC. LPA was added to quiescent RASMC at the
concentrations indicated above each lane. Total RNA (6 µg per
lane) was isolated from cells incubated with LPA for 1 .5 h,
and TF mRNA levels were determined by northern blotting.
Rat TF cDNA fragment (685 bp) was used as a probe. 28S and
1 8S rRNA were visualized by ethidium bromide staining.
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Fig. 2. Time course of LPA induction of TF mRNA. LPA
(25µM) was added to quiescent RASMC at the times
indicated. Total mRNA was isolated, and TF mRNA levels
were determined by Northern blot analysis. A rat TF cDNA
fra�ent (685bp) was used as a probe. 1 8S rRNA was
visualized by ethidium bromide staining.
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Fig.3. Nuclear protein binding activity is induced by
LPA at the Egrl site (not at SPl, NFKB, APl). Four

oligonucleotides (SPl ,NFKB, APl ,and Egrl) were
individually incubated with cell lysates from
unstimulated RASMCs, or cells stimulated with LPA for
the times indicated. Protein-DNA complexes were
analyzed by EMSA using a 6% polyacrylamide gel.
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Fig.4. Identification of the protein present in Egrl
protein_DNA complex II using Egrl _specific antibody. Egrl
oligonucleotides were incubated with nuclear extracts from
LPA-stimulated (lh) RASMCs in the absence or presence of2
µ1 ofEgrl antibody. The Egrl complexes are separated using 6
% nondenaturing acrylamide gel.
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Fig. 5. Time course of LPA induction of Egrl
mRNA. LPA (25µM) was added to quiescent
RASMC at the times indicated. Total mRNA was
isolated, and Egrl mRNA levels were determined by
Northern blot analysis. A rat Egrl cDNA fragment
(l.5kb.) was used as a probe.
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Fig.6. Egrl can transactivate the TF promoter. RASMCs · were
trasfected with a plasmid containing the wild type TF promoter cloned
upstream of the luciferase reporter gene [pTF (-258)]. Another set of
cells was cotransfected with the same plasmid and another plasmid
expressing Lac Z (pcDNA3. l/LacZ). A third set of cells was
cotransfected with both pTF (-258) and another plasmid expressing Egrl
(pSVKrox�24). Cells were starved for 48 hours before assaying
luciferase activity.
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Fig.7. Time course of LPA induction of Egrl
protein in RASMCs. Quiescent RASMCs were
stimulated with 25µM of LPA, and at the times
indicated, cell lysates were analysed by 10% SDS
PAGE and transferred to a polyvinylidine difluoride
membrane. Egrl protein was detected with antibody
against aegrl(C-19). Actin protein was used to
confirm equal protein loading.
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Fig.9. Localization of the LPA-responsive region in the Egrl
promoter. A series of deleted Egrl promoter constructs was made (see
,,
"experimental procedures ). Transfected RASMCs were made
quiescent for 48 h before the addition of 25 µM LPA for 3.5 h. Fold
induction is the luciferase (luc.) of transfected cells stimulated with
LPA compared with unstimulated contrls.
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Fig.10. Nuclear protein binding activity is
induced by LPA at the SRE site.

Radiolabelled SRE oligonucleotides were
incubated with cell lysates from unstimulated
RASMCs, or cells stimulated with LPA for the
times indicated. Protein-DNA complexes were
analyzed by EMSA using a 6% polyacrylamide
gel.
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Nuclear
protein
binding activity is induced by
LPA at the CRE site.
Radiolabelled
CRE
oligo
nucleotides were incubated with
cell lysates from unstimulated
RASMCs, or cells stimulated
with LPA for the times
Protein-DNA
indicated.
complexes were analyzed by
usmg
EMSA
a
6%
polyacrylamide gel.
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Fig.12. Specific nuclear protein binding activity is induced
by LPA at the SRE site. Cell lysates from quiescent
RASMCs or RASMCs stimulated with LPA for IO minutes
were pre- incubated for 20 minutes with: 50 molar excess of
unlabelled SRE oligonucleotides (3, 4), radiolabelled mutated
SRE oligonucleotides (5, 6), 2µ1 of SRF antibody (6, 7), 2µ1 of
phosphorylated SRF antibody (9, 10). They were then
incubated with radiolabelled SRE oligonucleotides for another
20 minutes (1, 2, 3, 4, 7, 8, 9, 10). Protein DNA complexes
were then analyzed by EMSA using a 6% polyacrylamide gel.
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Fig.13. Specific nuclear protein
binding activity is induced by LP A
at the CRE site. Cell lysates from
quiescent RASMCs or RASMCs
stimulated with LPA for 10 minutes
were pre- incubated for 20 minutes .
with: 50 molar excess of unlabelled
CRE oligonucleotides (1, 2),
SRE
mutated
radiolabelled
oligonucleotides (5, 6), 1 µl of CRE
antibody
(6,
7),
1 µl
of
phosphorylated CRE antibody (9,
10). They were then incubated with
radiolabelled CRE oligonucleotides
for another 20 minutes (1, 2, 3, 4, 7,
8, 9, 10). Protein DNA complexes
were then analyzed by EMSA using a
6% polyacrylamide gel.
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Fig.14.Functional analysis of the Egrl promoter. RASMCs were
transfected with th native Egrl promoter (-140/+21) or mutated Egrl
promoter constructs [(-140/+21)dmSRE and (-140/+21)dmCRE)].
Transfected cells were starved for 48h before the addition of LPA
(25µM) for 3h. Fold induction is the luciferase activity of transfected
cells stimulated with LPA compared with unstimulated controls (n =
number of experiments; in each, transfections were performed in
duplicates).
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Fig.15. Northern blot analysis shows that
pretreatment of quiescent RASMCs with
PTX, R031, PD98059, 00126 block LPA
induced TF mRNA, whereas, G073122,
073122, and 073343 were not effective.
Quiescent RASMCs were stimulated with
LPA (25 µM) alone for 1 .5 hor after
pretreatment
with PTX (1 6h), RO31 ,
PD98059, UO126, 006976, U73122, and
U73343 (each for 30 min.) in the
concentrations indicated above. A rat TF
cDNA fragment (685bp) was used as a probe.
28S and 1 8S rRNA were visualized by
ethidium bromide staining.
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Fig.1 6. Northern blot analysis shows that pretreatment of
quiescent RASMCs with chelerythrin chloride and GF
block LPA-induced TF mRNA. Quiescent RASMCs were
stimulated with LPA (25µM) alone for 1.5 h or after

pretreatment with chelerythrin chloride and GF (each for 30
min.) in the concentrations indicated above. A rat TF cDNA

fragment (685bp) was used as a probe. 28S and 1 8S
rRNA were visualized by ethidium bromide staining.
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Fig.17. Northern blot analysis shows that pretreatment of quiescent
RASMCs with U0-126, SB, and Sp block LPA-induced TF mRNA.
Quiescent RASMCs were stimulated with LPA (25µM) alone for 1.5 h or
after pretreatment with Resveratrol, SB, Sp (each for 30 min.) in the
concentrations indicated above. A rat TF cDNA fragment (685bp) was
used as a probe. 28S and 1 8S rRNA were visualized by ethidium
bromide staining.
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Fig.18. Northern blot analysis shows that pretreatment of quiescent
RASMCs with PTX (120ng/ml), UO-126 (l0µM), GF (µM), and
Resveratrol (100 µM) block LPA-induced Egr-1 mRNA, whereas, SB
(2,5µM), Sp (2µM), U73122 (5µM) was not effective. Quiescent RASMCs
were stimulated with LPA (25µM) alone for 1.5 h or after pretreatment with
PTX (120ng/ml) for 16h, UO-126 (lOµM), GF (µM), and Resveratrol (100
µM), SB (2,SµM), Sp (2µM), U73 122 (SµM) (each for 30 min.). Total mRNA
was isolated, and Egrl mRNA levels were determined by northern blot
analysis. A rat Egrl cDNA fragment (1.Skb.) was used as a probe.
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Fig.19. Northern blot analysis shows that LPA-induced
TF mRNA was only blocked in quiescent RASMCs
infected by PKCE-dn. Total mRNA was isolated , and
TF mRNA levels were determined by Northern blot
analysis. A rat TF cDNA fragment (685bp) was used
as a probe.
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Fig.20. Northern blot analysis shows that LPA-induced TF
mRNA was not blocked in quiescent RASMCs infected by
PKC f.. Total mRNA was isolated , and TF mRNA levels
were determined ey Northern blot analysis. A rat TF
cDNA fragment (685bp) was used as a probe.
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Fig.21. LPA stimulates ROS release in RASMCS. Serum starved cells
were incubated with luminol and HRP and treated with either LPA
(25µM) alone or pre-treated with NAC for 30 min and then treated with
LPA (25µM). chemiluminescence was recorded immediately at 10
seconds intervals and then every 5 minutes after 30 minutes. For clarity,
data from some time points are not shown in the graph.
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Fig.22. Northern blot analysis shows that LPA
induction of TF mRNA is blocked by
antioxidants.
Quiescent
RASMCs
were
stimulated with LPA (25 µM) for 1. 5 h alone or
after pretreatment with Na F. [sodium formate
{l0OmM)] for 24h, Desf. [Desferoxamine
(50mM)], NAC [N-Acetyl Cysteine {lOmM)], DPI
[diphenyleneiodonium chloride (25µM)] for 30
minutes each. A rat TF cDNA fragment (685bp)
was used as a probe. 28S and 1 8S rRNA
were visualized by ethid ium bromide staining.
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Fig.23. PTX (Gai inhibitor) does not block LPA-induced ROS release in
RASMCS. Quiescent RASMCs were incubated with luminol and HRP, pre
treated with PTX for 16 h and then treated with LPA (25µM).
Chemiluminescence was recorded immediately at 10 seconds intervals and
then every 5 minutes after 30 minutes. For clarity, data from some time
points are not shown in the graph.
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Fig.24. GF (PKC inhibitor) does not block LPA-induced ROS release
in RASMCS. Quiescent RASMCs were incubated with luminol and
HRP, ,stimulated with LPA (25µM) alone or after pre-treatment with GF
for 30 minutes. Ch�miluminescence was recorded immediately at 60
seconds intervals and then every 5 minutes after 30 minutes. For clarity,
data from some time points are not shown in the graph.
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(1 0µM) for 30 minutes. Chemiluminescence was recorded immediately at
60 seconds intervals and then every 5 minutes after 30 minutes. For
clarity, data from some time points are not shown in the graph.
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Fig.26. LPA stimulates AA release in RASMCS. Release of [3H]AA in
the extracellular medium was measured in the presence of 0.1% albumin.
Results are expressed as the percent of total incorporated cellular
radioactivity.
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Fig.27. Time course of AA induction of TF mRNA. AA
(l0µM) was added to quiescent RASMC at the times indicated.
Total mRNA was isolated, and TF mRNA levels were
determined by Northern blot analysis. A rat TF cDNA fragment
(685bp) was used as a probe. 1 8S rRNA was visualized by
ethidium bromide staining.
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Fig.28. AA stimulates ROS release in RASMCS. Serum
starved cells were incubated with luminol and HRP and
treated with either AA (1 0µM) alone or pre-treated with
NAC (1 0µM) for 30 min and then treated with AA (1 0µM).
chemiluminescence was recorded immediately at 1 0 seconds
intervals and then every 5 minutes after 30 minutes. For
clarity, data from some time points are not shown in the
graph.
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Fig.29. Northern blot analysis shows that AA induction of TF
mRNA is blocked by antioxidants. Quiescent RASMCs were
stimulated with AA (SOµM) for 1.5 h alone or after pretreatment
with Na F. [sodium formate (lOOmM)] for 24h, Desf.
[Desferoxamine (50mM)], NAC [N-Acetyl Cysteine (lOmM)], DPI
[diphenyleneiodonium chloride (25µM)] for 30 minutes each. A rat
TF cDNA fragment (685bp) was used as a probe. 28S rRNA was
visualized by ethidium bromide staining.
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Fig.30. Northern blot analysis shows that LPA induction of TF mRNA is
blocked by PLA2 inhibitors. Quiescent RASMCs were stimulated with LPA
(25µM) for 1 .5 h alone or after pretreatment with the following PLA2 inhibitors:
MAFP (l OµM), ARA (aristolochic acid, lOµM), BPB (l OµM), Bel { lOµM), and
MJ33 (l OµM), each for 30 minutes. A rat TF cDNA fragment (685bp) was used
as a probe. 28S and 1 8S rRNA were visualized by ethidium bromide staining.
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Fig.31. ARA (PLA2 inhibitor) blocks LPA-induced ROS release in
RASMCS. Quiescent RASMCs were incubated with luminol and HRP and
treated with either LPA (25µM) alone or pre-treated with ARA (l oµM) for
30 min and then treated with LPA (25 µM). Chemiluminescence was
recorded immediately at 60 seconds intervals and then every 5 minutes after
30 minutes. For clarity, data from some time points are not shown in the
graph.
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Fig.32. Bel (PLA2 inhibitor) blocks LPA-induced ROS release in RASMCs.
Quiescent RASMCs were incubated with luminol and HRP and treated with
either LPA (25 µM) alone or pre-treated with Bel (5 µM) for 30 min and then
treated with LPA (25 µM). Chemiluminescence was recorded immediately at 60
seconds intervals and then every 5 minutes after 30 minutes.
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Fig.33. MJ33 (PLA2 inhibitor) blocks LPA-induced ROS release in
RASMCs. Quiescent RASMCs were incubated with luminol and HRP and
treated with either LPA (25µM) alone or pre-treated with MJ33 (l OµM) for
30 min and then treated with LPA (25µM). Chemiluminescence was
recorded immediately at 60 seconds intervals and then every 5 minutes
after 30 minutes. For clarity, data from some time points are not shown in
the graph.
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Fig.34. Western bolt analysis shows that Anti-oxidants do not block
LPA-induced MAPK. Quiescent RASMCs were stimulated with LPA
(25µM) alone for 3 minutes or after pretreatment with Na F. [sodium
formate (l OOmM)] for 24h, Desf. [Desferoxamine (50mM)], NAC [N
Acetyl Cysteine (l OmM)], DPI [diphenyleneiodonium chloride (25µM)]
for 30 minutes each. Cell lysates were analysed by 8% SOS-PAGE and
transferred to a polyvinylidine difluoride membrane. Phosphorylated
MEK protein was detected by its specific antibody.
91

l�AA -- uo 126 + LPA I
4.5
4
3.5
E 3
..: 2.5
E 2
-g 1 .5
1
0.5
0

0

5

10

1 5 20

25

30 35 40 45

50 55

60

65

Time (min)
Fig.35. U0-126 (MAPK inhibitor) blocks AA-induced ROS release in
RASMCs. Quiescent RASMCs were · incubated with luminol and HRP
and treated with either AA (10µM) alone or after pre-treatment with UO126 (lOµM) for 30 minutes. Chemiluminescence was recorded
immediately at 60 seconds intervals and then every 5 minutes after 30
. minutes. For clarity, data from some time points are not shown in the
graph.
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Fig.36. Northern blot shows that calcium
is involved in LPA-induced TF mRNA.
Quiescent RASMCs were stimulated with
thapsigargin alone (l OµM) for 1 .5 h, LPA
alone (25µM) for 1 .5 h or after pretreatment
with BAPTA-AM (40µM) for 30 minutes. A
rat TF cDNA fragment (685bp) was used
as a probe. 28S and 1 8S rRNA were
visualized by ethidium bromide staining.
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Fig.37. BAPT-AM (intracellular calcium chelator) blocks LPA-induced
ROS release in RASMCs. Quiescent RASMCs were incubated with
luminol and HRP and treated with either LPA (25 µM) alone or pre-treated
with BAPT-AM (40µM) for 30 min and then treated with LPA (25µM).
Chemiluminescence was recorded immediately at 60 seconds intervals and
then every 5 minutes after 30 minutes. For clarity, data from some time
points are not shown in the graph.
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Fig.38. Northern blot shows that calcium is
involved in AA-induced TF mRNA. Quiescent
RASMCs were stimulated with AA alone
(50µM) for 1.5 h or after pretreatment with
BAPTA-AM (40µM) for 30 minutes. A rat TF
cDNA fragment (685bp) was used as a probe. 28S
and 1 8S rRNA were visualized by ethidium bromide
staining.
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Fig.39. BAPT-AM (intracellular calcium chelator) blocks AA-induced
ROS release in RASMCs. Quiescent RASMCs were incubated with
lurninol and HRP and treated with either AA (S0µM) alone or pre-treated
with BAPT-AM (40µM) for 30 min and then treated with AA (S0µM).
Chemiluminescence was recorded immediately at 60 seconds intervals and
then every 5 minutes after 30 minutes. For clarity, data from some time
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Fig.40. Induction of TF mRNA in response
to LPA in HASMC. LPA was added to

quiescent HASMC at the concentrations
indicated above each lane. Total RNA (6 µg
per lane) was isolated from cells incubated
with LPA for 1.5 h, and TF mRNA levels were
determined by northern blotting. Human TF
cDNA fragment (641 bp) was used as a probe.

97

LPA

+

untreated

+

+

+

+

+

PIX GF(5µ.M) GF(l0µ.M) Resv. GO 073122

TF
Fig.41. Northern blot analysis shows that pretreatment of quiescent
HASMCs with PTX, GF, Resveratrol block LPA-induced TF
mRNA,whereas, GO73122, and 073122 were not effective. Quiescent
HASMCs were stimulated with LPA (25 µM) alone for 1.5 h or after
pretreatment
with PTX (120ng/ml for 16h), 006976
(l OOµM),Resveratrol (l OOµM), and U73122 (5µM) (each for 30 min.) A
human TF cDNA fragment (641bp) was used as a probe.
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Fig.42. Northern · blot analysis shows that
pretreatment of quiescent HASMCs with 00126
and PD block LPA-induced TF mRNA. Quiescent
HASMCs were stimulated with LPA (25µM) alone for
1 .5 h or after pretreatment with UO126 ( l 0µM) and
PD (3µM). A human TF cDNA fragment (641 bp) was
used as a probe.
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Fig.43. Northern blot analysis shows that pretreatment of
quiescent HASMCs with R031 and chelerythrin chloride
block LPA-induced TF mRNA, whereas SP and SB were
not effective. Quiescent HASMCs were stimulated with LPA
(25 µM) alone for 1.5 h or after pretreatment with RO3 1
(.SµM), chelerythrin chloride (3µM), SP (5µM), and SB (2µM).
A human TF cDNA fragment (641 bp) was used as a probe.
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Fig.44. Northern blot analysis shows that LPA induction of
TF mRNA is blocked by DPI. Quiescent RASMCs were
stimulated with LPA (25)µM) for 1.5 h alone or after
pretreatment with Na F. [sodium formate (lOOmM)] for 24h,
Desf. [Desferoxamine (50mM)], NAC [N-Acetyl Cysteine
(lOmM)], DPI [diphenyleneiodonium chloride (25µM)] for 30
minutes each. A human TF cDNA fragment (641bp) was used as
a probe.
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Fig.45. Northern blot analysis shows that AA induction
of TF mRNA is blocked by DPI in HASMCs. Quiescent
HASMCs were stimulated with AA (50µM) for 1.5 h
alone or after pretreatment with Na F. [sodium formate
(lOOmM)] for 24h, Desf. [Desferoxamine (50mM)], NAC
[N-Acetyl Cysteine (lOmM)], DPI [diphenyleneiodonium
chloride (25µM)] for 30 minutes each. A rat TF cDNA
fragment (685bp) was used as a probe.
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